Your browser doesn't support javascript.
loading
Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation Burden.
Gabriel, Aurélie A G; Atkins, Joshua R; Penha, Ricardo C C; Smith-Byrne, Karl; Gaborieau, Valerie; Voegele, Catherine; Abedi-Ardekani, Behnoush; Milojevic, Maja; Olaso, Robert; Meyer, Vincent; Boland, Anne; Deleuze, Jean François; Zaridze, David; Mukeriya, Anush; Swiatkowska, Beata; Janout, Vladimir; Schejbalová, Miriam; Mates, Dana; Stojsic, Jelena; Ognjanovic, Miodrag; Witte, John S; Rashkin, Sara R; Kachuri, Linda; Hung, Rayjean J; Kar, Siddhartha; Brennan, Paul; Sertier, Anne-Sophie; Ferrari, Anthony; Viari, Alain; Johansson, Mattias; Amos, Christopher I; Foll, Matthieu; McKay, James D.
Afiliação
  • Gabriel AAG; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Atkins JR; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Penha RCC; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Smith-Byrne K; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Gaborieau V; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England.
  • Voegele C; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Abedi-Ardekani B; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Milojevic M; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Olaso R; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Meyer V; Université Paris-Saclay, The French Alternative Energies and Atomic Energy Commission (CEA), Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France.
  • Boland A; Université Paris-Saclay, The French Alternative Energies and Atomic Energy Commission (CEA), Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France.
  • Deleuze JF; Université Paris-Saclay, The French Alternative Energies and Atomic Energy Commission (CEA), Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France.
  • Zaridze D; Université Paris-Saclay, The French Alternative Energies and Atomic Energy Commission (CEA), Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France.
  • Mukeriya A; Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
  • Swiatkowska B; Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
  • Janout V; Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland.
  • Schejbalová M; Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
  • Mates D; First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Stojsic J; National Institute of Public Health, Bucharest, Romania.
  • Ognjanovic M; Department of Thoracic Pathology, Service of Pathology, University Clinical Centre of Serbia, Belgrade, Serbia.
  • Rashkin SR; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • Kachuri L; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • Hung RJ; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Kar S; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • Brennan P; Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada.
  • Sertier AS; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
  • Ferrari A; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Viari A; Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
  • Johansson M; Fondation Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Lyon, France.
  • Amos CI; Fondation Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Lyon, France.
  • Foll M; Fondation Synergie Lyon Cancer, Plateforme de bioinformatique Gilles Thomas, Lyon, France.
  • McKay JD; Inria Centre de Recherche Grenoble Rhone-Alpes, Grenoble, France.
J Natl Cancer Inst ; 114(8): 1159-1166, 2022 08 08.
Article em En | MEDLINE | ID: mdl-35511172
BACKGROUND: Germline genetic variation contributes to lung cancer (LC) susceptibility. Previous genome-wide association studies (GWAS) have implicated susceptibility loci involved in smoking behaviors and DNA repair genes, but further work is required to identify susceptibility variants. METHODS: To identify LC susceptibility loci, a family history-based genome-wide association by proxy (GWAx) of LC (48 843 European proxy LC patients, 195 387 controls) was combined with a previous LC GWAS (29 266 patients, 56 450 controls) by meta-analysis. Colocalization was used to explore candidate genes and overlap with existing traits at discovered susceptibility loci. Polygenic risk scores (PRS) were tested within an independent validation cohort (1 666 LC patients vs 6 664 controls) using variants selected from the LC susceptibility loci and a novel selection approach using published GWAS summary statistics. Finally, the effects of the LC PRS on somatic mutational burden were explored in patients whose tumor resections have been profiled by exome (n = 685) and genome sequencing (n = 61). Statistical tests were 2-sided. RESULTS: The GWAx-GWAS meta-analysis identified 8 novel LC loci. Colocalization implicated DNA repair genes (CHEK1), metabolic genes (CYP1A1), and smoking propensity genes (CHRNA4 and CHRNB2). PRS analysis demonstrated that these variants, as well as subgenome-wide significant variants related to expression quantitative trait loci and/or smoking propensity, assisted in LC genetic risk prediction (odds ratio = 1.37, 95% confidence interval = 1.29 to 1.45; P < .001). Patients with higher genetic PRS loads of smoking-related variants tended to have higher mutation burdens in their lung tumors. CONCLUSIONS: This study has expanded the number of LC susceptibility loci and provided insights into the molecular mechanisms by which these susceptibility variants contribute to LC development.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estudo de Associação Genômica Ampla / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estudo de Associação Genômica Ampla / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article